Loading data for SION — first visit, this takes a few seconds.

Alert

Sionna Therapeutics Inc. (SION)

NasdaqGM: SION · Real-Time Price · USD

5.87

-0.19 (-3.14%)

At close: Aug 28, 2026, 3:59 PM

5.89

+0.27%

After-hours: 7:58 PM

The price, the headline numbers and the latest news, in one place.

-3.14% (1D)

Bid	35.98
Market Cap	265.03M
Revenue (ttm)	n/a
Net Income (ttm)	-97.38M
	n/a
	-2.08
	n/a
	-2.32
P/B (ttm)	1.00
P/S (ttm)	n/a
Earnings Date	Nov 5, 2026

Ask	64.74
Volume	782,913
Avg. Volume (20D)	1,802,549
Open	5.97
Previous Close	6.06
Day's Range	5.82 - 6.06
52-Week Range	4.01 - 54.97
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About SION

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector th...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 7, 2025

Employees 59

Stock Exchange NasdaqGM

Ticker Symbol SION

Website https://www.sionnatx.com

Full Company Profile

Financial Performance

In 2025, Sionna Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -75.27M, an increase of 22.01%.

Financial Statements

Earnings Surprise

Sionna Therapeutics has released their quarterly earnings on Aug 6, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.
EPS of -0.66 misses estimates by -0.01, with -60.98% YoY decline.

Next Earnings Release

Sionna Therapeutics Inc. is scheduled to release its earnings on Nov 5, 2026, before market opens.
Analysts project revenue of ... Upgrade

News

1 week ago · Motley Fool

Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead

Don't bet against Vertex Pharmaceuticals in cystic fibrosis.

2 weeks ago · Simply Wall St.

Sionna Therapeutics (SION) Resets After Trial Miss, Is The Discount Now Too Deep?

Sionna Therapeutics (SION) is back in focus after reporting topline results for its cystic fibrosis programs, including a Phase 2a proof of concept miss for SION-719 and supportive Phase 1 data for SI...

2 weeks ago · Simply Wall St.

Sionna Therapeutics (SION) Is Down 86.8% After Halting SION-719 And Refocusing Its CF Pipeline – Has The Bull Case Changed?

Sionna Therapeutics recently reported that its lead cystic fibrosis candidate SION-719 failed to meet the key activity endpoint in a Phase 2a proof-of-concept trial as an add-on to Trikafta, prompting...

2 weeks ago · MT Newswires

Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says

Vertex Pharmaceuticals (VRTX) has multiple potential catalysts coming from its portfolio that provid

2 weeks ago · Simply Wall St.

Sionna Therapeutics (SION) Stock Still Looks Cheap After The 90% Fall

Sionna Therapeutics stock has fallen sharply in recent sessions, yet the valuation checks suggest it is not a clear bargain even after the sell off. The share price reset sits alongside a low overall ...

Page 1 of 2

Sionna Therapeutics Inc. (SION)